Close
Almac
Achema middle east
Drug Research

FDA approves Amphastar Enoxaparin Sodium Injection

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Business & Industry

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
Clinical Trials

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.
Business & Industry

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.
- Advertisement -

The US Food and Drug Administration has approved Amphastar Pharmaceuticals’ abbreviated new drug application for Enoxaparin Sodium Injection.The approval has been granted for 100mg/ml and 150mg/ml strengths.

Enoxaparin Sodium Injection is the generic version of Lovenox of Sanofi-aventis and is indicated for the treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction.

Under an agreement signed with Watson Pharmaceuticals, Amphastar is responsible to supply the drug to Watson, which will be responsible to market, sell and distribute Enoxaparin Sodium Injection in the US.

Latest stories

Previous article
Dey Pharma to provide EpiPen Auto-Injectors
Next article
Theraclone doses first patient in Phase 1 TCN-032 drug trial

Related stories

Business & Industry

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
Clinical Trials

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.
Business & Industry

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.
Business & Industry

Modernizing Governance Structures for Faster Portfolio Decisions

Accelerate pharmaceutical R&D decision-making by implementing modern governance frameworks that establish clear decision rights, defined escalation pathways and cross-functional ownership while maintaining strategic alignment and rigor.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives.

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
Redefining success metrics in pharmaceutical portfolio management

Redefining Success Metrics in Pharma Portfolio Management

Digital platforms transforming pharmaceutical portfolio management

Digital Platforms are Transforming how Pharma Portfolios are Managed